Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr;31(2):156-65.
doi: 10.1097/AUD.0b013e3181c351f2.

Drug delivery for treatment of inner ear disease: current state of knowledge

Affiliations
Review

Drug delivery for treatment of inner ear disease: current state of knowledge

Andrew A McCall et al. Ear Hear. 2010 Apr.

Abstract

Delivery of medications to the inner ear has been an area of considerable growth in both the research and clinical realms during the past several decades. Systemic delivery of medication destined for treatment of the inner ear is the foundation on which newer delivery techniques have been developed. Because of systemic side effects, investigators and clinicians have begun developing and using techniques to deliver therapeutic agents locally. Alongside the now commonplace use of intratympanic gentamicin for Meniere's disease and the emerging use of intratympanic steroids for sudden sensorineural hearing loss, novel technologies, such as hydrogels and nanoparticles, are being explored. At the horizon of inner ear drug-delivery techniques, intracochlear devices that leverage recent advances in microsystems technology are being developed to apply medications directly into the inner ear. Potential uses for such devices include neurotrophic factor and steroid delivery with cochlear implantation, RNA interference technologies, and stem-cell therapy. The historical, current, and future delivery techniques and uses of drug delivery for treatment of inner ear disease serve as the basis for this review.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Abou-Halawa AS, Poe DS. Efficacy of increased gentamicin concentration for intratympanic injection therapy in Meniere's disease. Otol Neurotol. 2002;23:494–502. - PubMed
    1. Alzamil KS, Linthicum FH., Jr. Extraneous round window membranes and plugs: possible effect on intratympanic therapy. Ann Otol Rhinol Laryngol. 2000;109:30–32. - PubMed
    1. Battista RA. Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 2005;132:902–905. - PubMed
    1. Batts SA, Raphael Y. Transdifferentiation and its applicability for inner ear therapy. Hear Res. 2007;227:41–47. - PubMed
    1. Beck C, Schmidt CL. 10 years of experience with intratympanally applied streptomycin (gentamycin) in the therapy of Morbus Meniere. Arch Otorhinolaryngol. 1978;221:149–152. - PubMed

Publication types

MeSH terms

Substances